CN1887297A - Medicine composition for delaying senility and raising immunity and its prepn - Google Patents
Medicine composition for delaying senility and raising immunity and its prepn Download PDFInfo
- Publication number
- CN1887297A CN1887297A CNA2006101097211A CN200610109721A CN1887297A CN 1887297 A CN1887297 A CN 1887297A CN A2006101097211 A CNA2006101097211 A CN A2006101097211A CN 200610109721 A CN200610109721 A CN 200610109721A CN 1887297 A CN1887297 A CN 1887297A
- Authority
- CN
- China
- Prior art keywords
- group
- pharmaceutical composition
- improves
- immunity
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses one kind of medicine composition prepared with freeze dried sheep placenta powder and hepialus paecilomyce powder. The medicine composition has the effects of delaying senility and raising immunity. Experiments show that the medicine composition can raise foot sole swelling degree, increase PFC number, raise serum hemolysin, raise carbon clearance index, raise serum SOD activity, raise glutathione peroxidase activity, and lower myocardial lipofuscin content or propanedial content.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and preparation technology thereof, the pharmaceutical composition and the preparation technology thereof of particularly a kind of slow down aging, raising immunity.
Background technology
Aging is a kind of idiopathic necessary process that As time goes on any multicellular organism produces, generally be meant with advancing age, and a series of physiologys that produce and the variation of anatomical terms, show as: wrinkle, mottle (senile plaque), cutis laxa, eye pouch occurs, the colour of skin is dark and gloomy, alopecia and white hair, insomnia, tired, dizzy nervous, constipation, blood-fat and blood sugar raises, arthritis, visual deterioration, sexual disorder or the like, because aging makes human metabolism function and immunity degradation, the danger that causes various diseases increases greatly, as flu, apoplexy, senile dementia, heart disease, hypertension, the endocrine disturbance, cancer etc.
Human body self has a cover immune system, when running into poisoning intrusion, will come kill virus by spontaneous generation antibody (disease-resistant factor), makes human body that certain resistance against diseases be arranged, Here it is body immunity.Everyone immunity is different, and the people that immunity is strong is difficult for sick, and the weak people one of immunity runs into virus attack, just easily brings out various diseases.Immunologic hypofunction very easily causes infection such as antibacterial, virus, fungus, so the most direct performance of hypoimmunity is exactly liable to illness.Because of often ill, increased the weight of the consumption of body, thus generally have a delicate constitution, performances such as malnutrition, lethargy, fatigue and weak, appetite depression, sleep disorder, sick, have an injection and take medicine the normal potluck that just gets married.Each sick all very long time ask and could recover, and usually show effect repeatedly.If things go on like this can cause health and intelligence development bad, also easily bring out major disease.
People have adopted the whole bag of tricks for realizing the purpose of slow down aging, life-saving, raising immunity, and except that taking regular exercise, adopting maximum methods is exactly to take various food and the health foods that have slow down aging, improve immunity function.Along with people's improving constantly to quality of life, grow with each passing day to the demand with slow down aging, immunoloregulation function health food in market, it is imperative to develop a kind of effect health food with slow down aging, raising immunity function remarkable, without any side effects.
Summary of the invention
The object of the invention is to disclose a kind of pharmaceutical composition and preparation technology thereof.
The present invention seeks to be achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention consists of: frozen dry powder of sheep placenta 1-10 weight portion, peacilomyce hepiahi bacterium powder 1 weight portion.
Above-mentioned two flavor crude drug preferred weight proportionings are as follows:
Frozen dry powder of sheep placenta 2 weight portions, peacilomyce hepiahi bacterium powder 1 weight portion;
Frozen dry powder of sheep placenta 5 weight portions, peacilomyce hepiahi bacterium powder 1 weight portion;
Or frozen dry powder of sheep placenta 9 weight portions, peacilomyce hepiahi bacterium powder 1 weight portion.
Get the above-mentioned raw materials medicine, add conventional adjuvant,, make clinical acceptable forms according to common process, as: granule, capsule, drop pill, tablet, oral liquid etc.
Frozen dry powder of sheep placenta raw material of the present invention can directly be buied from market, or Placenta caprae seu ovis is made through cryotherapy technology.Cryogenic temperature freezing drying is operated according to freeze-drying curve, and below 20 ℃, high temperature is below 50 ℃ subzero for cryogenic temperature low temperature.
The effect that pharmaceutical composition of the present invention has slow down aging, improves immunity.Experimental result shows that pharmaceutical composition of the present invention improves swelling degree of the paw, improves PFC quantity, improves serum hemolysin, improves carbon and clean up index, improve serum activity of SOD, improve glutathione peroxidase activity, reduce myocardium lipofuscin content or reduce mda content; Prolong the fruit bat maximum life span, and pharmaceutical composition of the present invention has no side effect.
Following experimental example and embodiment are used to further specify but are not limited to the present invention.
The immunoregulation effect experiment of 1 medicament composition capsule of experimental example
Laboratory animal: 2 in Kunming female secondary mice in age, body weight 18-22g is divided into 4 groups at random by body weight, and body weight is through T check no significant difference (p＞0.05) between group.Dosage is selected: being tried thing is that the human body recommended dose is the approved product (embodiment of the invention 1 preparation) of 1.98g/60kg.bw every day, and the dose,equivalent of mice is equivalent to 10 times of human body recommended dose.Respectively with human body recommend 5 times, 10 times and 30 times as low (0.165g/kg.bw), in (0.33g/kg.bw), high (0.990g/kb.bw) dosage.Take administration by gavage, irritate stomach every day once, matched group is irritated the distilled water of equal volume.Each is organized mice and is tried thing continuously after 4 weeks, measures the following index.
Delayed allergy (DTH) (the sufficient sole of the foot thickens method)
Every mice of lumbar injection 0.2mL2% (V/V) SRBC immunity.Behind the immunity 4d, measure left back sufficient sole of the foot thickness,, measure left back sufficient sole of the foot thickness behind the 24h then at measuring point subcutaneous injection 0.020mL20% (V/V) SRBC with micrometer caliper.Same position is measured three times, averages.The degree of representing DTH with the difference of sufficient sole of the foot thickness before and after attacking.
The influence of table 1 pair normal mouse delayed allergy (X ± SD)
| Group | Dosage (g/kg.bw) | Number of animals (only) | Swelling degree of the paw difference (mm) | The P value |
| Dosage group high dose group in the blank group low dose group | 0 0.165 0.330 0.990 | 10 10 10 10 | 1.04±0.20 1.30±0.28* 1.32±0.16** 1.30±0.13** | - 0.0259 0.0024 0.0021 |
*: significant difference (p＜0.05) is relatively arranged with the blank group
*: significant differences (p＜0.01) is relatively arranged with the blank group
As seen from the above table, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, basic, normal, high dosage group swelling degree of the paw improves 25% (p＜0.05), 27% (p＜0.01), 25% (p＜0.01) respectively.
Antibody-producting cell (PFC) detects
Every mice of lumbar injection 0.2mL20% (V/V) SRBC immunity.Behind the 5d, get mouse spleen and make the splenocyte liquid that cell concentration is 5 * 106/mL.The dissolving agarose is made 1% solution, in 48.0 ℃ of water bath heat preservations, mixes with Hank ' the s liquid of 2 times of concentration of equivalent, divides to be filled in the small test tube.Every pipe 0.50mL adds 0.050mL10%SRBC and 0.010mL splenocyte suspension, and mixing is poured on the slide rapidly, and incubation 1h in 37.0 ℃ of calorstats is added in complement in the slide groove, incubation 1.5h again.The counting plaque.
The influence of table 2 couple normal mouse PFC (X ± SD)
Unit: log
10Plaque number/full spleen
| Group | Dosage (g/kg.bw) | Number of animals (only) | PFC | The P value |
| Dosage group high dose group in the blank group low dose group | 0 0.165 0.330 0.990 | 10 10 10 10 | 4.73±0.23 5.11±0.21** 5.03±0.27* 5.06±0.13** | - 0.0013 0.161 0.0019 |
*: significant difference (p＜0.05) is relatively arranged with the blank group
*: significant differences (p＜0.01) is relatively arranged with the blank group
As seen from the above table, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, the PFC quantity of basic, normal, high dosage group improves 8% (p＜0.01), 6% (p＜0.05) and 7% (p＜0.01) respectively.
The mensuration of serum hemolysin
Every mice of lumbar injection 0.2mL20% (V/V) SRBC immunity.Behind the 5d, pluck eyeball and get blood in centrifuge tube, place 1h, the centrifugal 10min of 2000r/min collects serum.400 times of mice serum SA liquid dilutions, the SRBC0.50mL of the mice serum 1.00mL, 10% (V/V) of adding dilution, complement (with the dilution in 1: 10 of SA liquid) 1.00mL successively.Other establishes the not control tube of increase serum (replacement of SA liquid).Put ice-water bath cessation reaction behind 37.0 ℃ of water-bath 20min.2000r/min。Centrifugal 10min.Get supernatant 1.00mL, Dou Shi reagent 3.00ml is in vitro, and the SRBC0.25mL that gets 10% (V/V) simultaneously adds reagent 4.00mL as the HD50 pipe.After placing 10min, 540nm wavelength place measures optical density value.Result of the test is represented with half hemolysis value (HC50).
The influence of table 3 pair normal mice serum hemolysin (X ± SD)
| Group | Dosage (g/kg.bw) | Number of animals (only) | HC50 | The P value |
| Dosage group high dose group in the blank group low dose group | 0 0.165 0.330 0.990 | 10 10 10 10 | 107±65 176±80* 158±70 172±64* | - 0.0490 0.1085 0.0348 |
*: significant difference (p＜0.05) is relatively arranged with the blank group
As seen from the above table, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, HC50 low, high dose group improves 64% (p＜0.05) and 61% (p＜0.05) respectively.
Mice carbon is cleaned up experiment
To the india ink of 5 times of every mouse tail vein injection dilutions, 0.1mL/10g body weight.Treat to clock immediately after prepared Chinese ink injects.Respectively at inject behind the prepared Chinese ink 1,10min gets blood 0.020mL and adds to the 2.00mL sodium carbonate liquor, 600nm wavelength place measures optical density value, compares with sodium carbonate liquor.Other gets the liver spleen and weighs.Represent macrophage phagocytic function with phagocytic index.
The influence that the carbon of table 4 pair normal mouse is cleaned up (X ± SD)
| Group | Dosage (g/kg.bw) | Number of animals (only) | α | The P value |
| Dosage group high dose group in the blank group low dose group | 0 0.165 0.330 0.990 | 10 10 10 10 | 6.7±0.6 6.7±0.7 6.7±0.8 7.2±0.5* | - 0.9704 0.8723 0.0362 |
*: significant difference (p＜0.05) is relatively arranged with the blank group
As seen from the above table, what per os gave the mice various dose is tried thing after 4 weeks, with the blank group relatively, the carbon of high dose group is cleaned up index and is improved 7% (p＜0.05).
The delaying senility function experiment of 2 medicament composition capsules of experimental example
Laboratory animal: healthy secondary Kunming kind 10 month female mices, be divided into 4 groups at random, body weight is through the no significant difference of t check between group.U.S.'s wild type Drosophila melanogaster (Origen K).Dosage is selected: being tried thing is that the human body recommended dose is the approved product (embodiment of the invention 2 preparations) of 1.98g/60kg.bw every day.The dose,equivalent of mice is equivalent to 10 times of human body recommended dose.Respectively with 5 times, 10 times of the human body recommended dose and 30 times as low (0.165g/kg.bw), in (0.330g/kg.bw), high dose (0.990g/kg.bw).Take administration by gavage, irritate stomach every day once, matched group is irritated distilled water.Each is organized mice and is tried thing continuously after 56 days, measures the following index.
Tried the influence of thing to aged mouse cardiac muscle lipofuscin
Take out cardiac muscle, behind removal connective tissue and the fat, weigh, add chloroform methanol extracting solution (2: 1) homogenate in homogenizer, extraction refers to brown matter 2-3 time, and extracting solution merges several times, is settled to 7.0mL.Extracting solution is changeed minutes centrifugal 10 minutes with 3000, get supernatant and be used to measure fluorescence intensity, excitation wavelength 360nm, radiation wavelength 450nm is a standard control with quinine sulfate (1 μ g/mL, 0.1mol/L sulphuric acid), its fluorescence intensity is decided to be 50 units (Is).Working sample fluorescence intensity (Ix) under this condition, chloroform methanol solution is blank.
Table 5 is tried thing to the influence of aged mouse cardiac muscle lipofuscin (X ± SD)
| Grouping | Tried agent amount (g/kg.bw) | Number of animals (only) | Cardiac muscle lipofuscin content (μ g/g organizes heavy) | The P value |
| Dosage group high dose group in the blank group low dose group | 0 0.165 0.330 0.990 | 10 10 10 10 | 11.2±5.2 7.4±4.0 6.3±3.4 7.4±4.4 | - 0.0798 0.0212 0.0902 |
*: significant difference (p＜0.05) is relatively arranged with the blank group
Last table shows that per os gives the aged mouse various dose and tried thing after 56 days, compares with the blank group, and middle dosage group cardiac muscle lipofuscin content reduces by 44% (p＜0.05)
Tried the influence of thing to aged mouse serum mda content
The mensuration of table 6 serum mda content
| Reagent | Standard pipe mL | The blank pipe of standard mL | Measure pipe mL | Measure blank pipe mL |
| 1,2, No. 3 mix reagents of standard substance (10nmol/mL) dehydrated alcohol serum | 0.100 - - 4.00 | - 0.100 - 4.00 | - - 0.100 4.00 | - - - 4.00 |
Behind the mixing, the centrifugal 10min of back 3500-4000r/min is taken out in 95 ℃ of water-baths (uncap and boil) 40 minutes, distilled water zeroing, 532nm place colorimetric.
Table 7 is tried thing to the influence of aged mouse serum mda content (X ± SD)
| Grouping | Tried agent amount (g/kg.bw) | Number of animals (only) | Serum mda content (nmol mL) | The P value |
| Dosage group high dose group in the blank group low dose group | 0 0.165 0.330 0.990 | 10 10 10 10 | 8.3±2.4 5.2±1.0** 4.5±0.5*** 4.8±0.7*** | - 0.0014 0.0002 0.0003 |
*: highly significant difference (p＜0.01) is relatively arranged with the blank group
* *: utmost point significant difference (p＜0.001) is relatively arranged with the blank group
Last exterior syndrome is bright, and per os gives the aged mouse various dose and tried thing after 56 days, compares with the blank group, low, in and high dose group serum mda content reduce by 37% (p＜0.01), 46% (p＜0.001) and 42% (p＜0.001) respectively.
Tried the influence of thing to the aged mouse serum activity of SOD
Table 8 serum superoxide dismutases vitality test
| Reagent | Measure pipe | Control tube |
| Reagent 1 (mL) serum (uL) reagent 2 (mL) reagent 3 (mL) reagent 4 (mL) distilled water (mL) | 1.000 15.0 0.100 0.100 0.100 0.500 | 1.000 - 0.100 0.100 0.100 0.515 |
| Mixing, 37 ℃ of water bath with thermostatic control 40min | ||
| Reagent 5, reagent 6, glacial acetic acid mixed liquor (mL) | 2.00 | 2.00 |
| Behind the mixing 10min, pour 1cm optical path cuvette into, distilled water zeroing, 550nm place colorimetric determination OD value | ||
To reach 50% o'clock pairing SOD amount be a unit to the SOD suppression ratio in every mL reactant liquor.
Table 9 is tried thing to the influence of aged mouse serum activity of SOD (X ± SD)
| Grouping | Tried agent amount (g/kg.bw) | Number of animals (only) | Serum activity of SOD (NU/Ml) | The P value |
| Dosage group high dose group in the blank group low dose group | 0 0.165 0.330 0.990 | 10 10 10 10 | 282±32 300±36 310±21* 301±21 | - 0.2618 0.0335 0.1287 |
*: relatively there were significant differences (p＜0.05) with the blank group
Per os gives the aged mouse various dose and is tried thing after 56 days, compares with the blank group, and middle dosage group serum activity of SOD improves 10% (p＜0.05).
Tried the influence of thing to aged mouse whole blood glutathione peroxidase activity
Get Mus blood 10 μ l and join in the 1mL distilled water, shake well is made diluting blood sample liquid.
Glutathion peroxidase in table 10 whole blood (GSH-Px) vitality test
| Reagent | Sample cell | Non-enzyme pipe | Blank pipe |
| GSH(mL) | 0.400 | 0.400 | - |
| Diluting blood sample liquid (mL) | 0.400 | - | - |
| Distilled water (mL) | - | 0.400 | - |
| 37 ℃ of water-baths 5 minutes | |||
| H 2O 2(Ml) 37 ℃ of pre-temperature | 0.200 | 0.200 | - |
| 37 ℃ of water-bath accurate responses 3 minutes | |||
| Metaphosphoric acid precipitated liquid (mL) | 4.00 | 4.00 | - |
| The centrifugal 10min of 3000r/min | |||
| Centrifuged supernatant (mL) | 2.00 | 2.00 | - |
| Distilled water (mL) | - | - | 0.400 |
| Metaphosphoric acid precipitated liquid (mL) | - | - | 1.60 |
| Na2HPO4(mL) | 2.50 | 2.50 | 2.50 |
| The DTNB liquid (mL) that develops the color | 0.500 | 0.500 | 0.500 |
| Chromogenic reaction 1min in the 420nm wavelength, reads the O.D value | |||
The blood GSH-Px unit of activity: regulation 1mL whole blood in 1min, the 1g[GSH of deduction non-enzyme reaction] reduce after, make 1g[GSH] to reduce by 1 be a unit of activity.
Table 11 is tried thing to the influence of aged mouse whole blood glutathione peroxidase activity (X ± SD)
| Grouping | Tried agent amount (g/kg.bw) | Number of animals (only) | GSH-PX (unit of activity number) | The P value |
| Dosage group high dose group in the blank group low dose group | 0 0.165 0.330 0.990 | 10 10 10 10 | 33.5±2.5 32.1±5.1 37.4±2.5** 36.5±3.1* | - 0.4515 0.0026 0.0267 |
*: relatively there were significant differences (p＜0.05) with the blank group
*: highly significant difference (p＜0.01) is relatively arranged with the blank group
Per os gives the aged mouse various dose and is tried thing after 56 days, compares with the blank group, and middle and high dosage group mice whole blood glutathione peroxidase activity improves 12% (p＜0.01) and 9% (p＜0.05) respectively.
The experiment of experimental example 3 life span of drosophila melanogaster
Experiment material: U.S.'s wild type Drosophila melanogaster (0rigen K) that Shanghai Railway Univ's medical college provides.Dosage is selected: establish a blank group and 4 dosage groups (embodiment of the invention 6 preparations), each dosage group feedstuff contains and is tried substrate concentration and be respectively: 0%, 0.02%, 0.06%, 0.18%, 0.54%.Detection method: ovum, larva, pupa and adult are all cultivated at 25 ± 1 ℃, in the biochemical incubator of relative humidity 40-70 (%).After will using normal feedstuff always and boiling into medicated porridge, be sub-packed in the aseptic culture test tube, every culture tube seals with aseptic sponge plug.The adult normal feedstuff was changed once on the 4th day, culture tube is lain in the incubator raise.Collecting the adult that hatches in 6 hours divides into groups.All not copulation of fruit bat of hatching in the scope at this moment.With the grouping of weighing behind the etherization.Select the close fruit bat of individual size.20 of every pipes, male and female divide supports.Each 200 of every group of female male drosophilas.Tried thing in the adult stage, tried thing and be incorporated in 50 ℃ of normal feedstuff that dissolve in advance, and keep respectively organizing the pH value unanimity, regularly added up fruit bat survival number and death toll every day.Until whole death.The average of the natural law of 20 fruit bats survivals of every group of last death is the maximum life span of this group, and experimental result is calculated average life and maximum life span and half death time.
Table 12 is tried the influence of thing to the fruit bat half death time
| Tried substrate concentration % | Sex | Sample number | The half death time (d) |
| 0 0.02 0.06 0.18 0.54 | ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ | 200 200 200 200 200 200 200 200 200 200 | 60 57 61 59 67 64 68 67 63 70 |
Table 13 is tried thing to the influence of life span of drosophila melanogaster (X ± SD)
| Tried substrate concentration % | Sex | Sample number | Average life (d) | The P value | Maximum life span (d) | The P value |
| 0 0.02 0.06 0.18 0.54 | ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ | 200 200 200 200 200 200 200 200 200 200 | 56.1±16.8 53.1±19.0 59.2±15.7 55.9±19.9 63.0±13.5*** 59.5±19.1*** 64.7±12.9*** 62.3±19.1*** 59.6±16.7* 65.4±16.2*** | - - 0.0594 0.1476 8.532×10 -6 9.679×10 -4 2.132×10 -8 1.992×10 -6 0.0375 1.379×10 -11 | 76.7±2.0 82.9±2.2 77.9±0.9 83.1±2.0 78.3±1.1*** 84.6±2.0* 79.7±1.2*** 86.3±1.0*** 79.3±1.7*** 85.3±1.3*** | - - 0.0195 0.8240 3.513×10 -3 0.0148 1.898×10 -5 4.491×10 -7 1.057×10 -4 2.389×10 -4 |
*: relatively there were significant differences (p＜0.05) with the blank group
* *: utmost point significant difference (p＜0.001) is relatively arranged with the blank group
Compare (being tried substrate concentration 0%) with the blank group, the female fruit bat maximum life span that is tried substrate concentration 0.02% prolongs 2% (p＜0.05).The female fruit bat half death time of being tried substrate concentration 0.06% prolongs 7 days, and average life prolongs 12% (p＜0.001), and maximum life span has prolonged 2% (p＜0.001); The male fruit bat half death time prolongs 7 days, and average life prolongs 12% (p＜0.001), and maximum life span has prolonged 2% (p＜0.05).The female fruit bat half death time of being tried substrate concentration 0.18% prolongs 8 days, and average life prolongs 15% (p＜0.001), and maximum life span prolongs 4% (p＜0.001); The male fruit bat half death time prolongs 10 days, and average life prolongs 17% (p＜0.001), and maximum life span prolongs 4% (p＜0.001).The female fruit bat half death time of being tried substrate concentration 0.54% prolongs 3 days, and average life prolongs 6% (p＜0.001), and maximum life span has prolonged 3% (p＜0.001); The male fruit bat half death time prolongs 13 days, and average life prolongs 23% (p＜0.001), and maximum life span has prolonged 3% (p＜0.001).
4 drug combination preparations of experimental example and the contrast of single crude drug immunoregulation effect
Laboratory animal: Kunming mouse is provided by Hebei province's Experimental Animal Center, and No. 04056, the moving word in quality certification Ji during the experimental observation, is raised the solid feed that provides with this center, freely drinks water.Dosage is selected: being tried thing is that the human body recommended dose is the approved product of 1.98g/60kg.bw every day, and the dose,equivalent of mice is equivalent to 10 times of human body recommended dose, recommends 5 times (0.165g/kg.bw) with human body, and other matched groups all adopt this dosage.
Mice hemolysin rust is given birth to the influence of ability
Get 60 of mices, body weight is 30 ± 3g, and male and female half and half are divided into 5 groups at random: normal group, model group, frozen dry powder of sheep placenta group, peacilomyce hepiahi bacterium powder group, this medicine group (embodiment of the invention 7 preparations).Normal group, model group are irritated stomach and are given and isopyknic distilled water, and all the other 3 groups of gastric infusion amounts are 0.165g/kg, every day 1 time, continuous 11 days.Except that normal group, all the other 4 groups of mices are pressed the 40mg/kg.d intraperitoneal injection of cyclophosphamide, for three days on end.The 6th day, each organized equal lumbar injection 5% chicken erythrocyte suspension of mice (0.2ml/ only).The 12nd day, each was organized mice and plucks eyeball and get blood, and centrifuging and taking serum with 100 times of serum dilutions, is got dilute serum 1ml with normal saline, and with 5% chicken erythrocyte suspension 0.5ml, 10% guinea pig serum 0.5ml mixes.In 37 ℃ of calorstats, behind the incubation 30min, place 0 ℃ of refrigerator stopped reaction, centrifugal.Get supernatant in Lambda12 type spectrophotometer in the 605nm colorimetric, measure absorbance, other establishes the blank product that do not add the mice serum measurement result and returns to zero.Carry out the t check.
The influence of table 14 pair mice hemolysin level (n=12, X ± S)
| Group | Number of animals (only) | Dosage (g/kg) | Serum hemolysin level (absorptance) |
| This medicine of normal group simulation group frozen dry powder of sheep placenta group peacilomyce hepiahi bacterium powder group group | 12 12 12 12 12 | Wait appearance 0.165 0.165 0.165 Deng appearance | 0.470±0.055 0.145±0.068△△△ 0.341±0.112▲▲▲★★★ 0.375±0.083▲▲▲★★★ 0.482±0.032▲▲▲ |
Annotate: model group and normal group be △ △ △ P＜0.001 relatively, △ △ P＜0.01, △ P＜0.05
Each medicine group and model group comparison ▲ ▲ ▲ P＜0.001, ▲ ▲ P＜0.01, ▲ P＜0.05
This medicine group and single medicine group be ★ ★ ★ P＜0.001 relatively, ★ ★ P＜0.01, ★ P＜0.05
Compare with normal group, the serum hemolysin level of simulation group significantly reduces, expression modeling success.Organized apparently higher than simulation by serum hemolysin level of each group of reagent thing, illustrate that each group is subjected to the be improved living hemolysin ability of rust of hypoimmunity mice of reagent thing, this medicine group is remarkable than other single medicinal material group effects.
The test of mice carbon clearance
Get 60 of mices, body weight is 30 ± 3g, and male and female half and half are divided into 5 groups at random: normal group, model group, frozen dry powder of sheep placenta group, peacilomyce hepiahi bacterium powder group, this medicine group (embodiment of the invention 1 preparation).Normal group, model group are irritated stomach and are given and isopyknic distilled water, and all the other 3 groups of gastric infusion amounts are 0.165g/kg, every day 1 time, continuous 7 days.Except that normal group, all the other 4 groups of mices are pressed the 40mg/kg.d intraperitoneal injection of cyclophosphamide, for three days on end.The 7th day, behind the gastric infusion 0.5h, each organized (the dilution in 1: 4 of mouse tail vein injection india ink, 0.1mol/10g), injection back 2min and 10min in the eye socket rear vein beard 20 μ l (with the absorption of 20 μ l autocontrol micropipets) that take a blood sample respectively, are dissolved in the 0.1%Na of 2 μ l
2CO
3In the solution, in 604nm place colorimetric determination absorbance, with the 0.1%Na that does not heal
2CO
3The solution zeroing.Get the Liver and kidney spleen and weigh, the calculation correction carbon granule is cleaned up index α.The result cleans up index (K) with carbon granule and proofreaies and correct carbon granule that to clean up index (α) be index, carries out t and checks.
Table 15 pair mice carbon granule is cleaned up the influence (X ± SD) of index and correction index
| Group | Animal (only) | Dosage (g/kg) | Clean up index (K) | Index (α) is cleaned up in correction |
| Normal group | 12 | Etc. appearance | 0.0145±0.0040 | 6.72±1.21 |
| Model group | 12 | Etc. appearance | 0.0036±0.0024 △△△ | 2.77±0.84 △△△ |
| The frozen dry powder of sheep placenta group | 12 | 0.165 | 0.0126±0.0025 ▲▲▲★★★ | 5.26±0.85 ▲▲▲★★★ |
| Peacilomyce hepiahi bacterium powder group | 12 | 0.165 | 0.0139±0.0036 ▲▲▲★★★ | 5.43±0.35 ▲▲▲★★★ |
| This medicine group | 12 | 0.165 | 0.0212±0.0018 ▲▲▲ | 6.81±0.27 ▲▲▲ |
Annotate: model group and normal group be △ △ △ P＜0.001 relatively, △ △ P＜0.01, △ P＜0.05
Each medicine group and model group comparison ▲ ▲ ▲ P＜0.001, ▲ ▲ P＜0.01, ▲ P＜0.05
This medicine group and single medicine group be ★ ★ ★ P＜0.001 relatively, ★ ★ P＜0.01, ★ P＜0.05
Compare with normal group, the carbon granule of model group is cleaned up index (K) and is proofreaied and correct carbon granule and clean up index (α) reduction (P＜0.001).Carbon granule is cleaned up index (K) and the correction carbon granule is cleaned up index (α) all can significantly raise by each group of reagent thing, and the immunity function that is improved is described, this medicine group is remarkable than single medicine group effect.
5 drug combination preparations of experimental example and single raw material life span of drosophila melanogaster experiment contrast
Experiment material: U.S.'s wild type Drosophila melanogaster (Origen K) that Shanghai Railway Univ's medical college provides.Dosage is selected: be divided into 4 groups at random: blank group, frozen dry powder of sheep placenta group, peacilomyce hepiahi bacterium powder group, this medicine group (embodiment of the invention 5 preparations).Feedstuff contains and is tried substrate concentration and be 0.06%.Detection method: ovum, larva, pupa and adult are all cultivated at 25 ± 1 ℃, in the biochemical incubator of relative humidity 40-70 (%).After will using normal feedstuff always and boiling into medicated porridge, be sub-packed in the aseptic culture test tube, every culture tube seals with aseptic sponge plug.The adult normal feedstuff was changed once on the 4th day, culture tube is lain in the incubator raise.Collecting the adult that hatches in 6 hours divides into groups.All not copulation of fruit bat of hatching in the scope at this moment.With the grouping of weighing behind the etherization.Select the close fruit bat of individual size.20 of every pipes, male and female divide supports.Each 200 of every group of female male drosophilas.Tried thing in the adult stage, tried thing and be incorporated in 50 ℃ of normal feedstuff that dissolve in advance, and keep respectively organizing the pH value unanimity, regularly added up fruit bat survival number and death toll every day.Until whole death.The average of the natural law of 20 fruit bats survivals of every group of last death is the maximum life span of this group, and experimental result is calculated average life and maximum life span.Carry out the t check.
Table 16 is tried thing to the influence of life span of drosophila melanogaster (X ± SD)
| Group | Sex | Sample number | Average life (d) | Maximum life span (d) |
| Blank this medicine of group frozen dry powder of sheep placenta group peacilomyce hepiahi bacterium powder group group | ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ | 200 200 200 200 200 200 200 200 | 53.2±14.5 50.4±16.7 55.2±12.6★★★ 52.6±17.3★★ 56.2±12.4△★★★ 53.0±15.2★★ 61.0±11.6△△△ 57.5±15.2△△△ | 72.5±2.0 80.3±1.8 75.9±1.2△△△★★★ 82.1±2.2△△△★★★ 76.3±1.5△△△★★★ 83.1±1.2△△△★★★ 79.7±1.2△△△ 86.5±1.0△△△ |
Annotate: blank group compares △ △ △ P＜0.001, △ △ P＜0.01, △ P＜0.05 with the medicine group
This medicine group and single medicine group be ★ ★ ★ P＜0.001 relatively, ★ ★ P＜0.01, ★ P＜0.05
Compare with the blank group, be subjected to each group of reagent thing all obviously to prolong fruit bat average life, maximum life span.This medicine group is compared significant difference than other single medicinal material groups, shows that this medicine group delaying senility function is better than single medicine group.
The specific embodiment
Embodiment 1: the preparation of tablet
Frozen dry powder of sheep placenta 2kg, peacilomyce hepiahi bacterium powder 1kg
Get the above-mentioned raw materials medicine, add conventional adjuvant,, make tablet according to common process.
Embodiment 2: capsular preparation
Frozen dry powder of sheep placenta 5kg, peacilomyce hepiahi bacterium powder 1kg
Get the above-mentioned raw materials medicine, add conventional adjuvant,, make capsule according to common process.
Embodiment 3: the preparation of granule
Frozen dry powder of sheep placenta 9kg, peacilomyce hepiahi bacterium powder 1kg
Get the above-mentioned raw materials medicine, add conventional adjuvant,, make granule according to common process.
Embodiment 4: the preparation of oral liquid
Frozen dry powder of sheep placenta 5kg, peacilomyce hepiahi bacterium powder 1kg
Get the above-mentioned raw materials medicine, add conventional adjuvant,, make oral liquid according to common process.
Embodiment 5: the preparation of tablet
Frozen dry powder of sheep placenta 1kg, peacilomyce hepiahi bacterium powder 1kg
Get the above-mentioned raw materials medicine, add conventional adjuvant,, make tablet according to common process.
Embodiment 6: the preparation of drop pill
Frozen dry powder of sheep placenta 3kg, peacilomyce hepiahi bacterium powder 1kg
Get the above-mentioned raw materials medicine, add conventional adjuvant,, make drop pill according to common process.
Embodiment 7: the preparation of injection
Frozen dry powder of sheep placenta 7kg, peacilomyce hepiahi bacterium powder 1kg
Get the above-mentioned raw materials medicine, add conventional adjuvant,, make injection according to common process.
Embodiment 8: the preparation of oral liquid
Frozen dry powder of sheep placenta 9kg, peacilomyce hepiahi bacterium powder 1kg
Get the above-mentioned raw materials medicine, add conventional adjuvant,, make oral liquid according to common process.
Claims (9)
1, a kind of slow down aging improves the pharmaceutical composition of immunity, it is characterized in that this pharmaceutical composition is made up of following crude drug: frozen dry powder of sheep placenta 1-10 weight portion, peacilomyce hepiahi bacterium powder 1 weight portion.
2, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition is by being made up of following crude drug: frozen dry powder of sheep placenta 2 weight portions, peacilomyce hepiahi bacterium powder 1 weight portion.
3, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition is by being made up of following crude drug: frozen dry powder of sheep placenta 5 weight portions, peacilomyce hepiahi bacterium powder 1 weight portion.
4, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition is by being made up of following crude drug: frozen dry powder of sheep placenta 9 weight portions, peacilomyce hepiahi bacterium powder 1 weight portion.
5,, it is characterized in that this pharmaceutical composition makes tablet, granule, capsule, oral liquid, drop pill or injection as claim 1,2,3 or 4 described pharmaceutical compositions.
6, have slow down aging in preparation, improve the application in the medicine of immunity as claim 1,2,3 or 4 described pharmaceutical compositions.
7, pharmaceutical composition as claimed in claim 5 has slow down aging in preparation, improves the application in the medicine of immunity.
8, application as claimed in claim 6, wherein slow down aging, improve immunity and be meant that pharmaceutical composition improves swelling degree of the paw, improves PFC quantity, improves serum hemolysin, improves carbon and clean up index, improve serum activity of SOD, improve glutathione peroxidase activity, reduce myocardium lipofuscin content or reduce mda content.
9, application as claimed in claim 7, wherein slow down aging, improve immunity and be meant that pharmaceutical composition improves swelling degree of the paw, improves PFC quantity, improves serum hemolysin, improves carbon and clean up index, improve serum activity of SOD, improve glutathione peroxidase activity, reduce myocardium lipofuscin content or reduce mda content.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101097211A CN100391476C (en) | 2006-08-07 | 2006-08-07 | Medicine composition for delaying senility and raising immunity and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101097211A CN100391476C (en) | 2006-08-07 | 2006-08-07 | Medicine composition for delaying senility and raising immunity and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1887297A true CN1887297A (en) | 2007-01-03 |
| CN100391476C CN100391476C (en) | 2008-06-04 |
Family
ID=37576577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101097211A Active CN100391476C (en) | 2006-08-07 | 2006-08-07 | Medicine composition for delaying senility and raising immunity and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100391476C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101544965B (en) * | 2009-05-06 | 2011-11-30 | 郑州诺必隆生物科技有限公司 | Coproduction process for extracting various bioactivators from pig placenta |
| CN111436602A (en) * | 2020-05-21 | 2020-07-24 | 廖宏溉 | Health food composition for delaying aging and improving immunity and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1091603C (en) * | 1999-09-23 | 2002-10-02 | 重庆润康药业有限公司 | Biological health article with immunity regulating function |
-
2006
- 2006-08-07 CN CNB2006101097211A patent/CN100391476C/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101544965B (en) * | 2009-05-06 | 2011-11-30 | 郑州诺必隆生物科技有限公司 | Coproduction process for extracting various bioactivators from pig placenta |
| CN111436602A (en) * | 2020-05-21 | 2020-07-24 | 廖宏溉 | Health food composition for delaying aging and improving immunity and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100391476C (en) | 2008-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| El Basuini et al. | The influence of dietary coenzyme Q10 and vitamin C on the growth rate, immunity, oxidative-related genes, and the resistance against Streptococcus agalactiae of Nile tilapia (Oreochromis niloticus) | |
| CN1223283C (en) | Phycomycetes food for improving physical ability of athletes and its preparation method | |
| CN1301666C (en) | Health food capable of raising immunity and its production process | |
| CN105595224A (en) | Sea cucumber dunaliella salina glucosan selenium preparation and preparation process | |
| CN110218756B (en) | Method for extracting selenium-rich sturgeon bone peptide with anti-aging effect and product | |
| CN1875996A (en) | A composition having anti-oxygenation function | |
| CN1701789A (en) | Nutrition replenisher containing sialic acid and its derivative | |
| CN106722934B (en) | Anti-aging health food containing earthworm and clam worm peptide-containing extract | |
| CN1529610A (en) | Remedies | |
| Abdullah et al. | Bioreactor-grown exo-and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment | |
| Nahavandi et al. | Investigation of the effect of diet containing Red algae (Laurencia caspica) on blood parameters and activity of digestive enzymes of goldfish (Carassius auratus) | |
| CN1902189A (en) | Plant-origin beta3-adrenoceptor agonist and use of the same | |
| CN103494187A (en) | Preparation method of tartary buckwheat vinegar egg juice | |
| CN1230160C (en) | Application of bamboo leaf total flavone in medicine for treating and preventing prostata disease and health-care-food | |
| CN106614158B (en) | A kind of Hementaria officianalis high-density breeding method | |
| WO2016141775A1 (en) | Uses of jilin ginseng oligopeptide in preparing food product or healthcare food product for combating fatigue | |
| CN1785054A (en) | Health-care food having anti-oxidation function and its prepn. method | |
| CN1887297A (en) | Medicine composition for delaying senility and raising immunity and its prepn | |
| RU2492867C1 (en) | Biologically active additive | |
| CN1240297C (en) | Peptide milk and its preparation technology | |
| CN1176697C (en) | Antisenility medicine composition and its prepn | |
| CN1249224C (en) | Superoxide dismutase composition and preparation method thereof | |
| CN115397263B (en) | Composition containing N-acetylglucosamine and preparation method and application thereof | |
| CN108991358A (en) | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method | |
| CN1067270C (en) | Nutritious health care medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: HANDAN MOLUODAN PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HANDAN PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 056005 No. 309 National Road, Handan Hebei Industrial Park, No. 18 Patentee after: Handan Moluodan Pharmaceutical Co., Ltd. Address before: 056005 No. 309 National Road, Handan Industrial Park, Hebei, 18 Patentee before: Handan Pharmaceutical Co., Ltd. |